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Abstract 
It is important to prevent protein/calorie malnutrition in children with end stage liver diseases prior to 
transplantation. This study involved 34 patients between the ages of 10 and 156 months (mean value 25.69 
months  32.2) (13 females and 21 males) on the liver transplant waiting list. Data collected as of three months 
before transplant and up to ten months after the procedure concerned gender, age, weight, height, Pediatric End 
Stage Liver Disease Score, baseline pathology, type of nutrition, type of transplant, immunosuppression, pulse 
steroid therapy, length of stay, and post transplant complications. Linear regression analysis showed that the 
length of hospital stay was 24.5 days more for females than for males, but also that intensive nutrition therapy 
shortens this stay for both female patients (P = 0.085) and younger patients (P = 0.023). The study population 
was divided into two groups according to the different nutritional therapies adopted. The Student’s t-test and 
Mann-Whitney test evidenced that the group receiving intensive nutrition therapy grew taller compared with the 
group following an oral diet (mean -1.37 and Prob = 0.043); that females grew taller compared to males (mean 
-1.65 +/- 0.56); and that there was an increase in height among the children in the group receiving intensive 
nutrition therapy despite the presence (-1.37 +/- 0.56) or absence (-14.8 +/- 5.44 and Prob = 0.035) of 
complications, and despite the administration (-1.03 +/- 0.33) or non administration (-1.48 +/- 0.55 and Prob = 
0.019) of steroids. Intensive nutrition therapy enhances the velocity of growth in height and shortens the length 
of hospital stay, thus optimizing the final prognosis of the baseline pathology.  
Keywords: nutrition therapy, pediatric patients, liver transplantation 
1. Introduction 
Malnutrition is a complication of chronic hepatic failure that significantly affects the prognosis of the pathology 
because it inhibits physical growth (De Russo, Ye, & Shepherd, 2007; Barshes, Chang, Karpen, Carter, & Goss, 
2006; Giammanco et al., 2003) and mental development, and lengthens the post-surgery recovery period with 
higher rate of complications (Alonso, 2008; Bucuvalas, Zeng, & Anand, 2004).  
Considerable research progress has been made in explaining the relationship between pretransplant nutritional 
status and posttransplant outcomes in pediatric liver transplant recipients. 
Protein-calorie malnutrition should be anticipated and prevented by early intervention with intensive nutritional 
support in the pretransplant period. 
This study aims at describing how proper nutritional therapy should be adjusted according to the nutritional 
screening of the pediatric patient, along with the intake of specific nutrients, eventually improving statural 
growth and reducing length of stay.    
As the study focuses on the influence of nutrition, the population was assessed on the basis of nutritional status 
and of the different nutritional therapies adopted, so as to assess whether outcomes changed accordingly. 
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2. Patients and Methods 
2.1 Study Population and Data Collection  
The study involved 34 subjects (13 f and 21 m) between the ages 10 and 156 months (mean value 25.69 months 
32.2) on the ISMETT (Istituto Mediterraneo per i Trapianti e Terapie ad Alta Specializzazione) liver transplant 
waiting list between November 2006 and December 2008.  
Data was collected as of three months before transplant and up to ten months after the procedure, specifically: 
gender, age, average daily weight and Z-score, average height and Z-score, Pediatric End Stage Liver Disease 
(PELD) Score (Bourdeaux et al., 2005; McDiarmid, Merion, Dykstra, & Harper, 2004) baseline pathology, 
surgical interventions before transplant, nutritional screening and evaluation, type of pre- and post-transplant 
nutrition, type of transplant, immunosuppression protocol and pulse steroid therapy, length of hospital stay, and 
post-transplant complications (Table 1).  
 
Table 1. Characteristics of sample group (number of patients 34) 
Age Gender 
< 12 months 11 (32.3%) 
13-24 months 10 (29.4%) 
25-156 months 13 (38.2%) 
(Females %) 13 (38.2%) 
Race 
(Europeans %) 28 (82.3 %) 
Pre-transplant procedures Intensive nutrition 
15 (44.1%) 19 (55,9%) 
 (Enterale + Oral) 15 (78.9%) 
(Enteral + Oral + Parenteral) 4 (21.0%) 
Type of transplant 
Split II-III 27 (79.4%) 
Split I-IV-VIII 2 (5.9%) 
Whole liver 5 (14.7%) 
Redo-split 3 (8.8%) 
Post-transplant complications 
Infections 6 (17.6%) 
Rejection 4 (11.7%) 
Vascular 6 (17.6%) 
Biliary 3 (8.8%) 
No complications 14 (41.1%) 
Standard immunosuppression Pulse steroids therapy 
26 (76.5%) 8 (23.5%) 
Pathology 
Biliary atresia 26 (76.4%) 
Wilson’s syndrome 1 (2.9%) 
Hepatoblastoma 1 (2.9%) 
Alpha1 antitrypsin deficiency 1 (2.9%) 
Alagille syndrome 1 (2.9%) 
Other 4 (11.7%) 
PELD score 
<18 16 (47%) >18 18 (52.9%) 
LOS in days 
> 30 22 (64.7%) < 30 12 (35.2%) 
 
2.2 Statistical Analysis 
Linear and logistic regression analyses were used to correlate the two dependent variables, length of stay and 
complications, with 11 independent variables. The values considered significant were P <0.5 and <0.1. 
Student’s t-test and the non-parametric two-tailed Mann-Whitney U test were applied to the two groups on 
different nutritional plans, and subdivided into four additional subgroups on the basis of gender, complications, 
immunosuppression therapy, and high-dose steroid therapy. The t-test will evidence the difference between the 
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mean values of the variables, while the Mann-Whitney test will show the sum of the theoretical and actual ranks. 
With regard to the Mann-Whitney test, we wanted to differentiate two distributions - treated children vs. 
non-treated children - meaning Prob < ι z ι = 0.05. In the presence of two different distributions, it is necessary to 
verify which group’s performance is better or worse than expected. If the sum of ranks of a group is lower than 
expected, this means that the group ranks higher than expected and vice versa. Therefore, as far as outcomes are 
concerned (body weight, height, velocity of growth, complications), our goal is for the sum of ranks of the 
children subject to treatment to be lower than expected (and therefore rank higher), and for the opposite to occur 
for the length of hospital stay. 
We also applied the t-test and the Mann-Whitney U test, dividing the population into two groups by type of 
transplant (cadaveric split-liver, segments II – III) and living-related split-liver, cadaveric whole organ, split I-IV 
and VIII and redo-cadaveric split-liver segments II - III.  
2.3 Independent Variables 
Gender: there were 13 females, 10 of whom were between the 3rd and 10th percentile, and 3 above the 10th 
percentile; and 21 males, 9 of whom between the 3rd and 10th percentile, and 12 above the 10th percentile.  
Age: age ranged between 10 and 156 months at the time of transplant (mean value 25.69 months  32.2). Eleven 
children (32.3%) were below the age of 12 months; 10 children (29.4%) between 12 and 24 months of age; and 
13 children (38.2%) between 25 and 156 months of age. Z-scores were used for height and weight to eliminate 
age differences. 
Body weight and height: the children’s growth was calculated on the basis of daily body weight and height 
(absolute values, percentages and Z-scores), measured 3 months before transplant, at the time of transplant, and 
10 months after transplant.  
x-Height Zscore=   
As part of the study we calculated the pre- and post-transplant velocity of growth by modifying the Tanner 
formula (Tanner, Whitehouse, & Takaishi, 1966) and using height as the reference value: 
Z velocity pre tx = (height tx – height pre tx) – (height 50th age tx/gender – height 50th age pre tx/ gender) 
Z velocity post tx = (height post tx – height tx) – (height 50th age post tx/ gender – height 50th age tx/ gender) 
Pathology and pre-transplant procedures: the study takes into account the following pathologies, all of which 
imply malabsorption and therefore slow down or stop growth: 26 cases of biliary tract atresia; 1 case of Wilson’s 
disease; 1 of hepatoblastoma; 1 of alpha1-antitrypsin deficit; 1 of Alagille syndrome; 1 of neonatal sclerosing 
cholangitis; 1 of congenital hepatic fibrosis; 1 of autoimmune hepatitis; and 1 of anicteric cholestasis. 
Of the 34 children, 23 of those affected by biliary atresia underwent a Kasai procedure; 3 underwent a 
redo-transplant; 2 underwent a transplant in a different facility; 1 received cycles of chemotherapy; and 8 did not 
undergo any pre-transplant procedure.  
The pre-transplant daily nutritional support, equal to 130-150% of the basal energy expenditure (Alonso, 2008; 
Greer, Lehnert, Lewindon, Cleghorn, & Shepherd, 2003; Novy, & Schwarz, 1997; Shepherd, 1996; Ramaccioni, 
Soriano, Arumugam, & Klish, 2000; Heubi, Helman, Melvin, & Shulman, 2002; Campos, Matias, & Coelho 
2002; Falcão & Tannuri, 2002), consisted of the supply of a lipid emulsion of long-chain 
triglyceride/medium-chain triglyceride in a ratio of 3:2, liposoluble vitamins, and micronutrients (Johnson, 
Young, Cotter, Lin, & Rowe, 1990; Lai & Chen, 2000; Marchesini, Fabbri, Bianchi, Brizi, & Zoli, 1996). Oral 
intake was the administration route of preference. If it failed to generate body weight gain, oral nutrition was 
integrated with cycles of enteral nutrition so as to reach the nutritional goals, administered via NG tube or 
gavage according to tolerance, and by gradually increasing formula volumes and concentrations. If the enteral 
route was not practicable, or if there was onset of complications, we administered parenteral nutrition (Holt, 
Miell, Jones, Mieli-Vergani, & Baker, 2000; Shepherd et al., 1991). 
Of the 34 children, 19 with weight and height between the 3rd and 10th percentile followed the intensive nutrition 
protocol, which calls for the alternation of oral nutrition and enteral nutrition, and at times (4 subjects) even 
parenteral nutrition. The other 15 children with weight and height between the 25th and 90th percentile followed 
an enriched and controlled oral diet. 
Immunosuppression: consisted of a dose of steroids (10 mg/kg of metilprednisolone IV) and 10-20 mg of 
intra-op basiliximab IV, followed by another dose of basiliximab on the 4th day after transplantation. In addition, 
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daily doses of tacrolimus (0.04 mg/kg BID PO) were given in order to reach the following blood trough levels: 
10-15 ng/mL during the first month after transplant, 5-10ng/mL between the 2nd and 6th month post-transplant, 
and 3-5 ng/mL thereafter as maintenance therapy. 
This protocol can vary depending on side effects (tacrolimus-related nephrotoxicity and neurotoxicity), on 
whether the donor or recipient suffer from particular pathologies, or on preexisting immunosuppression therapies, 
such as mycophenolate mofetil (450 mg/m2/dose for 2 weeks followed by 350 mg/m2/dose) or cyclosporine 
(10-15 mg/kg, doses adjusted in order to reach blood trough levels of 100-400 ng/ml).  
The hospital length of stay was longer than 30 days for 22 children (64.7%), and less than 30 days for 12 
children (35.3%). 
Complications: recorded during the ten months after transplantation were acute rejection (n. 4 = 11.7%); biliary 
complications (n. 3 = 8.8%); vascular complications such as hepatic artery and portal vein thrombosis (n. 6 = 
17.6%); viral, bacterial and fungal infections (n. 6 = 20.6%); other complications (8 = 23.5%); and death from 
cardiac arrest and infections (3 = 8.8%). There were no complications in 14 cases (41.1%), while “other 
complications” also included those that are not peculiar to liver transplantation. 
3. Results 
By applying linear regression analysis between the length-of-stay dependent variable and the 11 independent 
variables,  
LOS = β0 + β1 PELD + β2 gender + β3 Z-score h + β4 Z-score w + β5 nutrition + β6 transplant + β7 age at transplant + β8 immunosuppression +  
β9 complications + β10 intensive nutrition females + β11 intensive nutrition per age 
where β0 is a constant, and β1 through β11 are the coefficients of the indicated variables, we observed two 
significant outcomes (p>0.05) related to gender and age (Table 2).  
 
Table 2. Linear correlation between LOS and 11 variables from admission to T5 
LOS Coef. Standard error P>|t| 95% Confidence Interval 
33 observations      
Pediatric end-stage liver disease 0.1964 0.36722 0.598 -0.5672 0.9600 
Gender 24.5110 11.7183 0.049 -0.1415 48.8806 
Height Z-score 3.6345 2.3409 0.135 -1.2336 8.5027 
Weight Z-score 1.4924 2.3790 0.537 -3.4550 6.4400 
Intensive nutrition -15.6643 11.3181 0.181 -39.2016 7.8730 
Transplant -11.2817 8.9494 0.221 -29.8932 7.3297 
Age at the time of tx -0.16003 0.1151 0.179 -0.3994 0.0793 
Immunosuppression 10.01194 8.6308 0.259 -7.9369 27.9608 
Complications 10.5472 6.2240 0.105 -2.3963 23.4907 
Intensive nutrition in females -24.6405 13.6134 0.085 -52.9511 3.6701 
Intensive nutrition per Age 0.7564 0.3094 0.023 0.1184 1.4000 
Constant 25.6633 15.1718 0.106 -5.8881 57.2148 
 
The first outcome indicates that the mean length of stay for females is 24.5 days (value of the coefficient) longer 
than for males; the second outcome indicates different lengths of stay for each additional year of age. Intensive 
nutrition works better on younger children by shortening their length of stay, and positively affects females as it 
decreases their days of hospitalization by approximately 24.6 days (value of the coefficient) (P<0.10). 
Furthermore, the results showed that intensive nutrition, though not statistically significant, reduced the mean 
length of stay. This means that the children receiving intensive nutrition had a shorter length of stay. 
Unfortunately the small sample size did not allow for a confirmation of this outcome statistically, which would 
require a larger sample and a longer time interval. By applying logistic regression analysis, as well, we compared 
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the post-transplant dependent variable (complications) with the 10 independent variables indicated above, but 
were unable to identify any predictor of complications (Table 3).  
 
Table 3. Correlation between complications and peri-operative variables from admission to T5 
 
In this analysis we took into consideration 10 independent variables and excluded the length of stay because the 
presence of complications implies a longer hospitalization. 
Complications = β0 + β1 PELD + β2 gender + β3 Z-score h + β4 Z-score w + β5 nutrition + β6 transplant + β7 age at transplant +  
β8 immunosuppression + β9 intensive nutrition females + β10 intensive nutrition per age  
The 34 children were divided into two groups: Group 0, consisting of 19 (55.8%) severely malnourished children 
subject to an intensive nutrition protocol (oral diet + enteral nutrition), 4 of whom also received parenteral 
nutrition, and Group 1 consisting of 15 children (44.2%) with a height above the 25th percentile following an oral 
diet alone.  
As regards the t-test, the statistically significant factor (Table 4) regards the height Z-score from admission to 
post-transplantation. Intensive nutritional therapy increased height in the patients in Group 0.  
 
Table 4. T-Test performed on the 2 groups following different nutrition protocols 
 Group 0 –Group 1
(mean) 
Standard error 95% 
Confidence 
Interval P value
LOS 0.94 6.66 -13.60 13.79 NS 
Height Z-score -1.37 0.45 -2.29 -0.44 S 
weight Z-score -0.28 0.46 -1.23 0.66 NS 
pre-tx speed of growth -0.37 1.24 -2.90 2.15 NS 
post-tx speed of growth -7.83 5.17 -18.66 2.98 NS 
complications -0.98 0.17 -0.45 0.25 NS 
 
In parallel, the Mann-Whitney test showed a significant increase in both height Z-score and height percentage 




Complications Coef. Standard error  P>|z| 95% Confidence  Interval 
33 observations          
pediatric end-stage liver disease 0.3638 0.0574 0.527 -0.0762 0.1490 
gender 0.57312 1.9375 0.767 -4.3707 3.2244 
height Z-score -0.2693 0.4203 0.522 -1.0931 0.5545 
weight Z-score -0.0044 0.3239 0.989 -0.6393 0.6304 
intensive nutrition -0.8636 1.9057 0.650 -2.8715 4.5989 
transplant -1.4201 1.5719 0.366 -4.5010 1.6608 
Age at transplant -0.0275 0.0193 0.155 -0.0655 0.0103 
immunosuppression 2.5227 1.7505 0.150 -0.9082 5.9538 
intensive nutrition in females -0.2467 2.2275 0.912 -4.1192 4.6126 
intensive nutrition per age 0.0513 0.0439 0.907 -0.0809 0.9126 
constant 1.1186 2.4231 0.644 -3.6306 5.8679 
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Table 5. Mann-Whitney Test: rank sums of the 2 groups following different nutrition protocols 
 Prob > ι z ι 
LOS 0.42 
absolute value of height 0.09 
 Height Z-score 0.043 
Percentage height  0.03 
pre-tx speed of growth 0.66 
post-tx speed of growth 0.02 
complications 0.86 
absolute value of weight 0.31 
weight Z-score 0.51 
percentage weight 0.22 
 
We further divided each of the two groups into 4 subgroups according to gender, complications, 
immunosuppression, and high dose steroid therapy, and applied the t-test and Mann-Whitney test. 
Comparison of the gender-related differences between the average values of the two groups receiving different 
types of nutrition showed that the females (3 in Group 0, and 10 in Group 1) receiving intensive nutrition grew 
more in height and body weight compared to the males (12 in Group 0, and 9 in Group 1) (Table 6), as reflected 
in their increase in height Z-score and percentage body weight.  
 
Table 6. T-Test performed on the 2 groups following different nutrition protocols and subgroups 
 
Likewise, the same occurred with the other test, with a significant increase in absolute values of female height 





 Subgroups Group 0 
– Group 1 
(mean) 
Standard error 95% Confidence Interval
Height Z-score Gender 
(females) 
-1.65 0.56 -2.91 -3.99 
Percentage weight  Gender 
(females) 
-47.32 19.26 -92.71 -1.93 
Percentage height Without 
complications 
-14.88 5.44 -26.79 -2.98 
Height Z-score  With 
complications 
-1.37 0.56 -2.55 -0.19 
Height Z-score Standard 
immunosuppression 
protocol 
-1.64 0.59 -2.94 -0.34 
Height Z-score Without steroid therapy -1.48 0.55 -2.64 -0.33 
Height Z-score With steroid therapy -1.03 0.33 -1.85 -0.19 
Percentage weight  With steroid therapy -53.69 14.85 -91.18 -16.2 
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Table 7. Mann-Whitney Test: rank sums of the 2 groups following different nutrition protocols and subgroups 
 Subgroups  Prob > ι z ι 
Absolute value of height  Gender (females) 0.042 
Percentage height Gender (females) 0.0425 
Percentage height Without 
complications 
0.0350 
Height Z-score Standard immunosuppression protocol 0.0070 
Height Z-score Without high steroid doses  0.0190 
 
Groups 0 and 1 were divided into two subgroups, one with complications (8 children from Group 0, and 12 
children from Group 1), and one without complications (7 children from each Group). The t-test (Table 6) and 
the Mann-Whitney test (Table 7) showed that intensive nutrition therapy positively affected the growth in height 
(percentage and Z-score) in both groups with and without complications.  
As regards the immunosuppression subgroup, the statistically significant values regard the subgroup that 
followed the standard protocol, since the small dimensions of the subgroup following the non-standard protocol 
did not allow for any measurable results. Among the patients receiving standard immunosuppression, those 
receiving intensive nutrition grew taller compared to those following a controlled oral diet alone (Table 6). In 
parallel, the Mann-Whitney test applied to the group receiving standard immunosuppression showed a 
significantly higher height Z-score in those receiving intensive nutrition (Table 7).  
The acute rejection experienced by 3 children was treated with a cycle of high dose steroid therapy for 3-6 days, 
gradually reduced based on improvement, in order to show if and how high steroid doses administered in case of 
rejection affect growth (Tables 6 and 7). The outcomes achieved with the t-Test showed the positive effect of 
intensive nutrition on the growth in height regardless of steroid therapy, and the outcome of the Mann-Whitney 
test was significant in relation to height in the group not subject to steroid therapy. 
In our study population of 34 children there were 27 split-liver procedures segments II-III (79.4%), 24 of which 
were cadaveric, and 3 of which were retransplants. In addition, there were 5 whole-liver transplants (14.7%); and 
2 split-liver right lobe segments I-IV-VIII (5.9%). We also divided the study population according to the type of 
transplant in Group 1, consisting of 24 children who underwent cadaveric split-liver transplant segments II-III, 
and Group 0, consisting of 10 children who underwent other types of transplants. When we applied the t-test and 
Mann-Whitney test, the outcomes showed a height increase among the group of cadaveric split-liver transplants 
of segments II-III compared to the group subject to other types of transplants (Tables 8 and 9).  
 
Table 8. T-Test performed on the 2 groups subject to different transplants 
 Group 0 
– Group 1 
(mean) 
Standard error 95% 
Confidence 
Interval P value 
Absolute value of height -3.1 3.71 -10.66 4.46 NS 
Height Z-score -1.16 0.5 -2.23 -0.09 S 
Percentage height -6.29 6.39 -19.32 6.74 NS 
Absolute value of weight 0.05 0.88 -1.79 1.89 NS 
Weight Z-score  -0.49 0.45 -1.43 0.44 NS 
Percentage weight  -27.24 17.75 -63.92 9.44 NS 
LOS 8.85 7.66 -7.61 25.33 NS 
Pre-tx speed of growth -1.76 1.12 -4.08 0.55 NS 
Post-tx speed of growth 7.35 9.83 -14.83 29.54 NS 
Complications 0.15 0.18 -0.23 0.54 NS 
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Table 9. Test di Mann-Whitney: rank sums of the 2 groups subject to different transplants 
 Prob > ι z ι 
Absolute value of height 0.0430 
Height Z-score 0.0222 
Percentage height  0.0233 
Absolute value of weight 0.875 
Weight Z-score 0.25 
Percentage weight 0.126 
LOS 0.307 
Pre-tx speed of growth 0.096 




Supplying appropriate and intensive nutrition to children who are severely malnourished at hospital admission 
contributes significantly to the success of transplantation in terms of growth in height and shorter hospital stays.  
In our study, the t-test and Mann-Whitney test confirmed the positive effects of nutrition on the growth in height 
of children receiving intensive nutrition compared with those following a regular oral diet alone, despite the fact 
that the former were far more malnourished than the latter upon admission, and had an average Z-score of -2.22 
± 1.97 compared with the average height Z -score of 0.54 ± 2.29 in Group 1.  
Furthermore, our data confirmed the greater effectiveness of intensive nutrition in shortening the length of 
hospital stay among females and younger patients, thus confirming the results of other studies (Renz et al., 2001; 
Bartosh, Thomas, Sutton, Brady, & Whitington; Saito et al., 2007). In some studies (Alonso, 2008; Bartosh et al., 
1999; Saito et al., 2007), the mean height Z-score of the population waiting for liver transplantation ranged 
between -1.0 and -1.75. The mean height Z -score of the 34 children in our study, which was -1.30 ± 2.11 at 
admission, was within this range. 
This mean value decreases if we consider that 19 of our children had a height between the 3rd and 10th percentile 
upon admission, and a mean height Z-score of -2.22 ± 1.97. These children (Group 0) followed an intensive 
nutrition protocol in the pre-transplant period, achieving a height Z-score of -1.95 ± 2.74 at the time of 
transplantation. So there was a slight improvement of the growth in height (from -2.22 to -1.95), though the 
values remained in the negative range.  
Despite intensive nutrition, growing in height is unquestionably difficult in the pre-transplant phase because of 
pathologies that prevent achieving “normal” standards.  
Shepherd et al. (1991), followed by Alonso (2008), observed that despite the intensive supply of calories, many 
children affected with cirrhosis and advanced chronic hepatitis fail to achieve normal growth, and their functions 
may continue to deteriorate, making transplantation the only possible solution. 
The children in Group 1 whose statural and ponderal growth at admission was above the 25th percentile had a 
height Z-score of 0.54 ± 2.29. These children followed a controlled oral diet in the pre-transplant period, 
reaching a height Z-score of 1.1 ± 1.84 at the time of transplantation. 
Linear regression analysis has confirmed that intensive nutrition therapy is more effective because it shortens the 
length of hospital stay for younger children. According to Saito et al. (2007), children below the age of two years 
affected with biliary tract atresia tend to grow faster despite severe pre-transplant malnutrition. According to 
Renz (2001) who divided his study population into 3 groups, as had Tanner et al. (1966), there are significant 
differences in terms of height Z-score and velocity of growth Z-score in the posttransplant period. He also 
emphasized the potential advantages of performing early liver transplantation during periods in which 
endocrinologic variables favor accelerated growth. Bartosh et al. (1999), in contrast with Codoner- Franch et al. 
(1994) believe that the best time to perform a transplant is not determined solely by age.  
According to the data, gender affects the length of hospital stay and growth (McDiarmid et al., 1999). On one 
hand, the average hospital stay for females is 24.5 (coefficient value) days longer than for males; on the other 
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hand, intensive nutritional therapy has proven to be more effective in decreasing the days of hospitalization (p = 
0.023) and increasing the growth in height and weight (mean= -1,65 and -47,32) among female patients. 
Comparing our outcomes with those in the literature (Renz et al., 2001), male patients experienced a minor delay 
in height growth at the time of transplantation, and a greater velocity of growth compared to female patients, 
while others (McDiarmid et al., 1999) have found no statistical significance in gender for affecting the height 
growth curve after transplantation. 
Intensive nutrition therapy enables the blocking of metabolic, endocrinologic, and immune-related alterations 
triggered by the organism in case of stress caused by a pathology or surgical procedure (Ingenbleek & Bernstein, 
1999). According to Spada et al. (2009), the high rate of successful transplants is strongly affected by the 
possibility of scheduling the transplant before the onset or development of critical clinical conditions and severe 
malnutrition. Although the linear regression coefficient of intensive nutrition does not indicate statistically 
significant values related to the impact of intensive nutrition on length of hospital stay, it is important to 
underline that this approach still achieves positive results. This means that the length of stay is shorter for 
children treated with intensive nutrition. Although De Russo (2007) believes that intensive nutrition improves 
growth and survival potential when adopted in a timely fashion, and in a quantitatively and qualitatively correct 
manner, he administered intensive nutrition to only 47.8% of the malnourished patients in his study and to 36% 
of them only a few days before the surgical procedure or discharge. 
Fourteen (41.2%) of the 34 children in our study did not experience any complications during the ten months 
after transplantation. The remaining 58.8% experienced complications, with 7 children experiencing more than 
one complication, thus requiring longer hospital stays.  
Three children (8.8%) died: 1 of cardiac arrest 7 days after transplant, and 2 of superinfections approximately 
2-3 months after transplantation. In order not to skew the statistical analysis, the length of hospital stay of the 
three deceased children was considered “very long” (more than 10 months). The overall post-transplant survival 
rate was 91.2%. 
Among the 34 patients there were 3 cases of portal vein thrombosis, frequently associated with biliary atresia 
secondary to preexistent hypoplasia, and immediately solved by thrombectomy; 3 cases of stenosis followed by 
thrombosis of the hepatic artery; and 4 cases of acute cell rejection confirmed by biopsy, and treated with high 
dose steroid therapy. Of these 4 cases, the sole child affected with mild rejection was treated only by increasing 
tacrolimus blood levels.  
Three children experienced biliary stenosis, which has a frequency of 10-30% and can depend on the anatomical 
and perfusional characteristics of the donor graft (Spada, Riva, Maggiore, Cintorino, & Gridelli, 2009). 
Infection-related complications are the most common and troublesome cause of post-transplant morbidity and 
mortality because of the presence of venous and vesical catheters, a lower immune defense secondary to 
immunosuppression, and the characteristics of the donor graft. Two children died of bacterial and fungal 
infections, 2 suffered from bacterial infections and 2 from viral infections. According to Bucuvalas et al. (2004), 
infectious complications during the initial post-transplant period significantly affect the short and long term 
success of transplantation. Saito et al. (2007) state that the complication that most affects the velocity of growth 
in height is hepatic vein stenosis, because it is difficult to arrive at an early diagnosis compared with other 
vascular stenoses and with biliary stenosis. 
The results of this analysis regard the subgroups with and without complications, and confirm the relevance and 
usefulness of intensive nutrition therapy. In fact, by applying the two tests to the subgroup without complications 
(7 children from Group 0, and 7 children from Group 1) it can be seen that the percentage height increased in the 
group receiving intensive nutrition (Tables 6 and 7), and that the height Z-score increased in the subgroup with 
complications (8 children in Group 0, and 18 children in Group) (Table 6).  
Twenty-nine of the 34 children received standard immunosuppression as per our protocol (basiliximab + 
metilprednisolone + tacrolimus). Only 5 patients received non standard immunosuppression (basiliximab + 
metilprednisolone + tacrolimus). Three of these 5 children were coadminstered mycophenolate: 2 were 
coadminstered cyclosporine, and 1 coadminstered lamivudine. 
Renz et al. (2001) compared 2 groups following two different immunosuppression protocols (ACp= azathioprine, 
cyclosporine, prednisone; CNp= mycophenolate, cyclosporine, prednisone) and found no significant differences 
between the two groups in terms of height and velocity of growth. In our analysis, the only statistically 
significant outcomes were the ones achieved by the group following the standard immunosuppression protocol: 
the children receiving intensive nutrition grew more in height (mean Z-score = -1.64 and P > 0.0070) compared 
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to the children receiving oral nutrition (Tables 6 and 7). 
It is known that exposure to steroids delays children’s growth (Alonso, 2008; Saito et al., 2007). In fact, most 
current immunosuppression protocols do not envisage the use of steroids (Spada et al., 2006; Sarna, Sipila, 
Vihervuori, Koistinen, & Holmberg, 1995) except in cases of severe acute rejection or autoimmune hepatitis. In 
our study, the differences between the mean height Z-scores measured in the subgroup that did not receive 
steroids (10 children in Group 0, and 16 in Group 1) showed that the group receiving intensive nutrition grew 
more in height. The same applies to the rank sums of the Mann-Whitney test (Tables 4 and 5). 
To be underlined is the fact that statistically significant outcomes were also achieved by the subgroup receiving 
steroid therapy and intensive nutrition (5 children in Group 0, and 3 in Group 1), namely an increase in height 
Z-score and body weight among the children subject to intensive nutrition therapy. This outcome, as in the case 
of complications, substantiates the importance of adopting an intensive nutrition strategy. 
In our study, the statistically significant results showed a height increase associated with cadaveric split-liver 
transplantation (segments II-III) compared to other types of transplant, while Renz et al. (2001) found no 
statistically significant difference between the height scores and velocity of growth among recipients of grafts 
from living donors, cadaveric split-liver donors, or whole-organ donors. This outcome further confirms that the 
split-liver technique has improved and is now comparable to the other techniques (McDiarmid, Anand, & 
Lindblad, 2004; Utterson et al., 2005; Bilik, Greig, Langer, & Superina, 1993; Whitington & Balistreri, 1991). 
The first split-liver procedures performed on segments II and III use to imply a longer hepatic ischemia time, 
thus affecting the outcomes of the transplant itself, with a high difficulty of recovery of the grafted organ (Spada 
et al., 2009). 
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